Comments
The board of directors of Venus Remedies will meet on Wednesday to consider and approve raising of funds by way of qualified institutional placement. Investors will keenly observe the price, timing and quantum of the QIP issue. The pharma major had reported a loss of ₹2.10 crore for the third quarter ended December 2016 against a loss of ₹25 lakh in the year-ago period. Sales declined to ₹85.36 crore (₹98.42 crore).
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.